Analysis of Dipyridamole Combined with Irbesartan Treatment on IgA Nephropathy and its Safety
Objective To explore the effect of dipyridamole combined with irbesartan on IgA nephropathy and its safety.Methods Retrospective methods analysis was performed on 88 patients with IgA nephropathy in our hospital from July 2013 to July 2016, Single drug group were treated with irbesartan treatment;combination group received dipyridamole combined with irbesartan in the treatment of.Comparison of two groups of patients with IgA nephropathy treatment effect before and after treatment for 24 hours urine protein, serum creatinine.Results The therapeutic effect of the combined group of patients with IgA nephropathy than the single drug group, P<0.05;two groups of patients before treatment and 24 hours urine protein, serum creatinine was not significant, P>0.05;combined treatment group after 24 hours urine protein, serum creatinine than the single drug group, P<0.05;united group of adverse reaction difference and the rate of single drug group was not significant, P>0.05.Conclusion Dipyridamole combined with irbesartan treatment on IgA nephropathy and its safety is good, can improve renal function and no obvious side effects, worthy of promotion.
NETL
NSTL
万方数据
维普
